SBIR/STTR Research Award
Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife
Award amount
$79,700Program and phase
SBIR · Phase IAward year
2006Award details
- Awarding agency
- Department of Agriculture
- Branch
- Not reported
- Recipient company
- MOLECULAR TARGETING TECHNOLOGIES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Y2FNW7N1V267
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Extensive worldwide reservoirs of rabies virus (RV) in wildlife and stray dogs continue to pose a serious risk of lethal infection of humans and cause a high economic burden. Immunization of wildlife and stray dogs with live vaccines is the only effective method to control and eventually eliminate rabies in carnivore species worldwide. In this application we propose to select canine adenovirus type-2 (CAV2) clones that optimally express the rabies virus (RV) G protein from previously engineered replication-competent CAV 2 - RVG constructs. These selected CAV 2-RVG viruses will be evaluated for safety and efficacy in laboratory animals as an initial proof of concept.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk
- Instantaneous Tumor Spray for Real-Time Surgical Guidance
- Topic 368: Biotherapy of Brain Tumors by Radioiodinated SapC-DOPS Nanovesicles
- Sprayable, Prompt Color Changing Dye to Delineate Ovarian Cancer During Surgery
- Topical Drug Treatment of Cutaneous Leishmaniasis
Research funding history
24 SBIR/STTR records share this UEI (1995–2023). Reported award amounts total $11,751,888. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Agriculture